US2019224325A1PendingUtilityA1

Drug composition for parenteral administration

48
Assignee: THERABIOPHARMA INCPriority: Jun 29, 2016Filed: Jun 28, 2017Published: Jul 25, 2019
Est. expiryJun 29, 2036(~10 yrs left)· nominal 20-yr term from priority
Inventors:Hideaki KakeyaMasashi KanaiNobuaki TakahashiTadashi HashimotoAtsushi ImaizumiHitomi Ozawa
A61K 47/549A61K 9/0019A61P 35/00A61K 31/12A61K 38/00A61K 31/223A61P 37/08A61K 31/7028A61K 31/185A61P 9/00A61P 25/28A61P 3/06A61P 29/00
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition for parenteral administration, including a water-soluble substance conjugate of curcumin as an active component.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for parenteral administration, comprising a water-soluble substance conjugate of curcumin as an active component. 
     
     
         2 . The pharmaceutical composition for parenteral administration according to  claim 1 , wherein the water-soluble substance is one or more members selected from the group consisting of glucuronic acid, sulfuric acid, glutathione, and an amino acid. 
     
     
         3 . The pharmaceutical composition for parenteral administration according to  claim 1 , wherein the water-soluble substance is one or more members selected from the group consisting of glucuronic acid and sulfuric acid. 
     
     
         4 . The pharmaceutical composition for parenteral administration according to  claim 1 , wherein the pharmaceutical composition for parenteral administration is a pharmaceutical composition selected from the group consisting of an anti-cancer agent, an anti-inflammatory agent, a cholesterol-lowering agent, an anti-allergic agent, a cognitive function improving agent, and a heart disease preventive and therapeutic agent. 
     
     
         5 . The pharmaceutical composition for parenteral administration according to  claim 1 , wherein the pharmaceutical composition for parenteral administration is a pharmaceutical composition for intravenous administration. 
     
     
         6 - 15 . (canceled) 
     
     
         16 . A curcumin therapy, comprising parenterally administering a water-soluble substance conjugate of curcumin. 
     
     
         17 . The curcumin therapy according to  claim 16 , wherein the water-soluble substance is one or more members selected from the group consisting of glucuronic acid, sulfuric acid, glutathione, and an amino acid. 
     
     
         18 . The curcumin therapy according to  claim 16 , wherein the water-soluble substance is one or more members selected from the group consisting of glucuronic acid and sulfuric acid. 
     
     
         19 . The curcumin therapy according to  claim 16 , wherein the curcumin therapy is a therapy selected from the group consisting of a cancer therapy, an anti-inflammatory therapy, a cholesterol-lowering therapy, an anti-allergic therapy, a cognitive function improving therapy, and a heart disease preventive therapy. 
     
     
         20 . The curcumin therapy according to  claim 16 , wherein the parenteral administration is intravenous administration.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.